Revolutionizing Pheochromocytoma Diagnosis with Next-Generation Molecular Imaging

The National Institutes of Health (NIH), through its National Institute of Child Health and Human Development (NICHD), is conducting a Phase 1 clinical trial (NCT00004847) to explore advanced PET/CT technology for the accurate diagnosis and localization of tumors in patients with pheochromocytoma and paraganglioma. Conventional imaging techniques like CT or MRI only provide anatomical information, lacking the specificity to differentiate between benign and malignant tumors or detect micrometastases. To address this, researchers are introducing radiopharmaceuticals [18F]-FDOPA (Fluorodopa F 18) and [18F]-6F-DA (6-Fluorodopamine) to visualize the specific metabolic activity of cancer cells, opening new horizons in precision diagnosis. Improved early detection rates are expected to increase the possibility of timely surgery, which is a key factor in dramatically improving the 5-year survival rate of patients.

Early Prediction through Multi-Biomarker and Genetic Analysis

This study goes beyond relying solely on imaging diagnostics and incorporates the analysis of multiple biomarkers, including catecholamines and their metabolites, such as metanephrine and methoxytyramine, in blood and urine. Accurate biochemical analysis effectively evaluates the activity of tumors within the body in a non-invasive manner and identifies high-risk individuals who may experience severe blood pressure fluctuations. Furthermore, genetic testing performed on the patient's DNA helps identify hereditary genetic mutations, which account for up to 40% of this disease. This provides a scientific basis for establishing proactive monitoring systems for family members and designing personalized treatment strategies.

Differentiated Mechanism of Action of [18F]-FDOPA and [18F]-6F-DA

The key drug in the study, [18F]-FDOPA, is a precursor to catecholamines and is rapidly absorbed into tumor cells through the activity of aromatic amino acid decarboxylase (AADC), allowing for a clear tracking of metabolic flow. Meanwhile, [18F]-6F-DA, developed by the NIH, targets the norepinephrine transporter (NET) on cell membranes and the vesicular monoamine transporter (VMAT), selectively accumulating in tumors. Its rapid elimination from the bloodstream maximizes the tumor-to-background ratio, enabling the detection of even small lesions. This functional imaging technology demonstrates clinical superiority by significantly reducing false-positive and false-negative rates compared to competing tests such as 123I-MIBG scintigraphy or FDG-PET.

Changing Competitive Landscape and Addressing Unmet Medical Needs

If left undiagnosed, pheochromocytoma can lead to life-threatening hypertensive crises or myocardial infarction during surgery or anesthesia. Currently, Novartis' 68Ga-DOTATATE (Netspot) and Lantheus' Azedra (I-131 MIBG) are competing in the diagnostic and therapeutic areas, and in 2025, Merck's Welireg (Belzutifan) was approved as the first oral treatment for metastatic patients, changing the treatment paradigm. These precision diagnostic radiopharmaceuticals are becoming essential for effective personalized treatment and are driving the related market. The molecular diagnostic data obtained through this clinical trial is expected to promote the growth of the companion diagnostics market and significantly improve the quality of life for patients.